Lyra Therapeutics (LYRA) Other Non-Current Assets (2019 - 2025)
Lyra Therapeutics (LYRA) recorded quarterly Other Non-Current Assets of $2.0 million in Q4 2025, little changed on a QoQ basis from $2.0 million in Q3 2025, and little changed YoY from $2.0 million in Q4 2024.
Lyra Therapeutics (LYRA) Other Non-Current Assets (2019 - 2025) Analysis & Trends
Lyra Therapeutics (LYRA) has reported Other Non-Current Assets for 7 consecutive years, with $2.0 million the latest figure, recorded in Q4 2025.
- Other Non-Current Assets for Q4 2025 came in at $2.0 million, changed 0.0% year-over-year; the trailing twelve-month figure through Dec 2025 was $2.0 million (changed 0.0% YoY), and the FY2025 annual result was $2.0 million, changed 0.0% from the prior year.
- Other Non-Current Assets for Q4 2025 stood at $2.0 million, roughly flat from $2.0 million in the prior quarter.
- The five-year high for Other Non-Current Assets was $3.8 million in Q1 2023, with the low at $245000.0 in Q3 2021.
- A 5-year average of $1.6 million and a median of $1.7 million in 2022 frame the typical range for Other Non-Current Assets.
- Across the five-year window, Other Non-Current Assets surged 903.04% in 2022 and tumbled 57.82% in 2023, its largest moves.
- Lyra Therapeutics' Other Non-Current Assets stood at $329000.0 in 2021, then surged by 903.04% to $3.3 million in 2022, then plunged by 57.82% to $1.4 million in 2023, then surged by 43.18% to $2.0 million in 2024, then changed by 0.0% to $2.0 million in 2025.
- The last three Other Non-Current Assets figures came in at $2.0 million (Q4 2025), $2.0 million (Q3 2025), and $2.0 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Lyra Therapeutics | 70,995.28 | 70,995.28 | - | 1.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.99 Mn |
| Sep 30, 2025 | 1.99 Mn |
| Jun 30, 2025 | 1.99 Mn |
| Mar 31, 2025 | 1.99 Mn |
| Dec 31, 2024 | 1.99 Mn |
| Sep 30, 2024 | 1.99 Mn |
| Jun 30, 2024 | 1.99 Mn |
| Mar 31, 2024 | 1.99 Mn |
| Dec 31, 2023 | 1.39 Mn |
| Sep 30, 2023 | 1.39 Mn |
| Jun 30, 2023 | 1.09 Mn |
| Mar 31, 2023 | 3.85 Mn |
| Dec 31, 2022 | 3.30 Mn |
| Sep 30, 2022 | 1.09 Mn |
| Jun 30, 2022 | 1.40 Mn |
| Mar 31, 2022 | 1.08 Mn |
| Dec 31, 2021 | 329,000.00 |
| Sep 30, 2021 | 245,000.00 |
| Jun 30, 2021 | 300,000.00 |
| Mar 31, 2021 | 329,000.00 |